结论：赛尼哌用于肾移植的免疫诱导治疗，可以预防和减少急性排斥反应的发生，安全性和耐受性好。
CONCLUSION: Zenapax used for immunity induction of renal transplantation can prevent and reduce the occurrence of acute reject reaction, it has safety and good tolerance.
结论HCV感染可抑制肾移植患者的细胞免疫功能，但不影响患者感染及急性排斥反应的发生率。
Conclusions HCV infection can suppress host cell immune function, but doesn't affect the rates of acute rejections and infections.
免疫荧光镜下示肾移植后急性肾小管间质性排斥反应。 免疫沉积物出现在肾小球间。
The immunofluorescence pattern with acute tubulointerstitial renal transplant rejection is shown here, in which immune deposits occur between glomeruli in the interstitium.
结论：未应用免疫抑制剂的条件下，吻合血管的颌下腺同种异体移植存在急性排斥反应。
Conclusion: Without using immunosuppressant, acute rejections exist in the allotransplantation of submandibular glands with blood vessel anastomosis.
通过对CD - 3抗体行免疫过氧化物酶染色，在心移植后急性细胞排斥反应的受者心脏心肌层中t淋巴细胞被显示出来。
An immunoperoxidase staining with antibody to CD-3, the T-lymphocytes in the myocardium involved in this acute cellular rejection phenomenon in a heart transplant recipient can be identified.
目的探讨青藤碱(SIN)对大鼠肾移植术后急性排斥反应免疫抑制作用的分子机制。
Objective To explore the molecular mechanism of immunosuppressive efficacy of alkaloid Sinomenine (SIN) against acute rejection following renal transplantation in rats.
目的了解HCV感染对肾移植患者免疫功能及感染和急性排斥反应的影响。
Objective To evaluate the impact of HCV infection on immune function, the incidence of acute rejections, and the frequency of infections in renal transplant patients.
在现代免疫抑制治疗下，急性排斥降到最低；然而，病人和长期的同种异体移植物生存并没有同时得到改善。
Acute rejection has been minimised under modern immunosuppression; however, patient and long-term allograft outcomes have not improved concurrently.
结论新型免疫抑制剂f K 5 0 6与MMF联合应用使急性移植肾排斥反应率降低，皮质激素用量减少。
Conclusion FK506 combined with MMF could decrease the occurrence of acute transplanted renal rejection and the dosage of Pred.
目的探讨青藤碱(SIN)对大鼠肾移植术后急性排斥反应免疫抑制作用的分子机制。
Objectives To evaluate the effects of the alkaloid sinomenine (sin) on t cell proliferation and acute rejection in rat renal allografts.
在新型免疫抑制剂应用下，急性排斥反应具有表现不典型、难治性排斥反应比例高等特点。
With novel immunosuppressive agents coming into clinical use, manifestations of acute rejection are not typical and refractory rejection is increasing.
在新型免疫抑制剂应用下，急性排斥反应具有表现不典型、难治性排斥反应比例高等特点。
With novel immunosuppressive agents coming into clinical use, manifestations of acute rejection are not typical and refractory rejection is increasing.
应用推荐